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Discrepancies between observed 
data and predictions from 
mathematical modelling of the 
impact of screening interventions 
on Chlamydia trachomatis 
prevalence
Joost smid, Christian L. Althaus  & Nicola Low  
Mathematical modelling studies of C. trachomatis transmission predict that interventions to screen and 
treat chlamydia infection will reduce prevalence to a greater degree than that observed in empirical 
population-based studies. We investigated two factors that might explain this discrepancy: partial 
immunity after natural infection clearance and differential screening coverage according to infection 
risk. We used four variants of a compartmental model for heterosexual C. trachomatis transmission, 
parameterized using data from england about sexual behaviour, C. trachomatis testing, diagnosis and 
prevalence, and Markov Chain Monte Carlo methods for statistical inference. In our baseline scenario, 
a model in which partial immunity follows natural infection clearance and the proportion of tests done 
in chlamydia-infected people decreases over time fitted the data best. The model predicts that partial 
immunity reduced susceptibility to reinfection by 68% (95% Bayesian credible interval 46–87%). The 
estimated screening rate was 4.3 (2.2–6.6) times higher for infected than for uninfected women in 2000, 
decreasing to 2.1 (1.4–2.9) in 2011. Despite incorporation of these factors, the model still predicted 
a marked decline in C. trachomatis prevalence. to reduce the gap between modelling and data, 
advances are needed in knowledge about factors influencing the coverage of chlamydia screening, the 
immunology of C. trachomatis and changes in C. trachomatis prevalence at the population level.
There is ongoing debate about the evidence to support screening for Chlamydia trachomatis (chlamydia) infection 
to reduce prevalence1–3. C. trachomatis is the most commonly reported bacterial sexually transmitted infection 
(STI) in high-income countries; in 2016, about 128,000 cases of C. trachomatis were diagnosed among young 
people aged 15–24 years in England4 and over 1 million in the United States of America5. C. trachomatis can cause 
pelvic inflammatory disease (PID) in women, which can lead to ectopic pregnancy and tubal factor infertility6. 
However, C. trachomatis infection is often asymptomatic, so screening has been promoted to detect and treat 
asymptomatic infection to prevent reproductive tract morbidity and reduce transmission. In England, screen-
ing for chlamydia increased considerably with the National Chlamydia Screening Programme (NCSP) in 2003. 
Through the NCSP, free opportunistic screening is offered to sexually active women and men under 25 years of 
age, with nationwide roll-out achieved in 2008. Testing coverage in young women increased from 4% in 2000 
to 35% in 20127. However, chlamydia prevalence, estimated in two cross-sectional population-based British 
National Surveys of Sexual Attitudes and Lifestyles (Natsal) was similar in adults aged 18 to 24 years; in 1999–
2001 (Natsal-2) women 3.1% (95% confidence interval, CI 1.8–5.2) and men 2.9% (1.3–6.3) and in 2010–2012 
(Natsal-3), women 3.2% (2.2–4.6) and men 2.6% (1.7–4.0)8,9.
Transmission dynamic modelling studies predict that screening at levels achieved by the NCSP in England 
should reduce C. trachomatis prevalence10. These modelling studies describe sexual networks and the dynamics 
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of infection transmission using different structures and levels of complexity11–14. In a simpler model, without 
detailed sexual behaviour, Lewis and White inferred changes in C. trachomatis prevalence and incidence using 
time-series data about chlamydia testing and diagnoses in England between 2000–20157,15. Their model output 
proposed that prevalence had declined as chlamydia testing increased and increased as testing levels fell. An 
assumption in these models, irrespective of structure, is that amongst people without symptoms suggestive of 
infection, testing for chlamydia is not influenced by the underlying risk of infection in the screened population. 
In reality, the NCSP in England primarily tests people at an increased risk of chlamydia and the dataset includes 
both screening tests done amongst asymptomatic individuals and tests done to diagnose symptomatic infection16. 
Further, with increasing chlamydia test coverage and falling test positivity7, if prevalence stayed at similar levels 
then the proportion of tests done in those at lower risk of infection must have increased.
Immunity also affects the model-predicted impact of screening if treatment inhibits the development of 
immunity otherwise experienced after natural clearance of infection17,18. In a model accounting for immunity, 
individuals that clear infection naturally are temporarily or partially protected from the force of infection which 
results in a less rapid turnover of C. trachomatis within the modelled population. This reduces the predicted 
impact of screening. Immunity is often not included as part of the natural history in C. trachomatis transmission 
models10 and, in practice, not much is known about the strength and duration of immunity. Clinical and animal 
studies suggest that immunity is probably partial instead of fully protective19,20. A recent modelling study found 
that a strong partial immunity reducing susceptibility to reinfection by 70–90% should be present to explain 
observed prevalence patterns21. In another modelling study, Johnson and colleagues estimated a period of immu-
nity of 6–17 years by fitting their model to chlamydia notification data, but they assumed that immunity was fully 
protective18.
In this paper, we use data about sexual behaviour and the prevalence of C. trachomatis in the general popu-
lation of Great Britain from Natsal-2 and Natsal-3 and time-series data about chlamydia testing and diagnoses 
in England and across the same time period. Using a C. trachomatis transmission model, we investigated two 
hypotheses about factors that might attenuate the effects of a chlamydia screening intervention: the existence of 
long-lasting partial immunity; and differential chlamydia test coverage according to the risk of being infected.
Methods
Data. Natsal is conducted by face-to-face and computer-assisted questionnaire amongst a stratified random 
sample of the resident population of Great Britain at ten year intervals since 1990. Natsal-2 includes data about 
12,110 respondents aged 16–44 years from 1999–2001, and Natsal-3 includes data about 15,162 respondents 
aged 16–74 years from 2010–201222,23. Starting with Natsal-2, a random sample of participants who have ever 
had sexual intercourse has been invited to provide a first catch urine sample, which is tested for the presence 
of C. trachomatis using a nucleic acid amplification test (3,608 respondents aged 18–44 years in Natsal-2 and a 
4,550 respondents aged 16–44 years in Natsal-3). We used data from heterosexual respondents between 16–44 
years about the number of new heterosexual partners in the last year, the respondent’s age at first heterosexual 
intercourse and the respondent’s age and partner ages at the time of first sexual intercourse with the first, second 
and third most recent heterosexual partner. We aggregated these data for both surveys because there were no 
significant differences for these variables between the datasets22.
We used estimates for the numbers of chlamydia tests and diagnoses from 2000 to 2011 in England from 
Chandra and colleagues7. The authors collated data from specialist and non-specialist settings in England, which 
include all NCSP tests from 2003 onwards. They applied assumptions to fill gaps in different data sources from 
2000 to 2007 and construct plausible minimum and maximum estimates for the numbers of tests and diagnoses 
each year. The data are presented for men and women separately in five-year age groups: 15–19, 20–24, 25–34 
and 35–44 year olds as rates per 100 persons, based on publicly available population denominators. For example, 
in 15–19 year old women, test coverage estimates were from 3.1 per 100 (minimum) to 9.7 (maximum) in 2000, 
increasing to 39.3 in 2011, with corresponding diagnosis rates of 891.1 to 2488.6 in 2000 and 2786.6 in 20117. In 
the baseline scenario of the model, we used the mid-points of the minimum and maximum estimates. As sensi-
tivity analyses, we also ran the model on the minimum and maximum estimates only. Chlamydia testing data did 
not distinguish between tests provided to people with symptoms suggestive of infection with C. trachomatis and 
screening tests amongst people without symptoms.
Chlamydia transmission model. We developed a mathematical model to describe heterosexual C. tra-
chomatis transmission in England from 2000 to 2011. The model uses differential equations and is described in 
detail in the Supplementary Information, part I; a brief summary is provided here. Model compartments and 
transmission rates are shown in Fig. 1 and Table 1.
The model describes the transmission of chlamydia among susceptible people (S), infected people with a 
primary infection (I), people that have recovered naturally (R) and people with a repeated infection (Y). People 
are further stratified by sex k (men, women), age a (15–17, 18–19, 20–24, 25–34 and 35–44 years old) and sexual 
activity class j (low, high, defined by the average number of new heterosexual partners per year). Detailed age 
mixing behaviour and mixing between activity classes is modelled using methods proposed in a previous publi-
cation, where we accounted for differences in sexual behaviour reported by men and women24. People can switch 
between activity classes at a rate that is proportional to the size of these classes25. There is a time-dependent force 
of infection λk,j,a that involves the per partnership transmission probability (β) and the heterosexual mixing pat-
terns between ages and sexual activity classes. A fraction q of all new infections is symptomatic, the remainder 
being asymptomatic. People in the recovered compartment are partially immune with a reduced susceptibility to 
reinfection.
We assumed that all symptomatically infected people receive a chlamydia test at rate χS and are subsequently 
treated. After treatment, symptomatically infected people become susceptible again at rate ωχS, where ω is the 
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probability of successfully clearing infection after treatment and 1/χS the average duration until treatment. 
Asymptomatically infected people can clear their infection naturally at rate γ, or are screened at a sex- and 
age-dependent rate χ t( )k a
A
,  that depends on time t. The chlamydia screening rate amongst asymptomatic individ-
uals differs according to the risk of being infected, which we refer to as differential screening coverage. In the 
model, we define differential screening coverage as the ratio of the screening rates in asymptomatic individuals 
who are infected with C. trachomatis and asymptomatic individuals who are uninfected. Arguably, this ratio 
decreases until 2011, as more screening is offered and becomes less targeted. We model differential screening 
coverage by a time-dependent parameter ηk,a (t) that decreases exponentially as a function of the total yearly 
number of screening tests Ξ t( )k a, :
η Ξ η η Ξ= + − − .t t( )( ) 1 ( 1)exp( ( )))) (1)k a k a k a, , 1 2 ,
η Ξ( )k a k a, ,  starts at η1 and converges to one as the number of tests Ξk a,  becomes large, reflecting the situation in 
which screening is distributed homogeneously among all people. We then calculated the screening rate in asymp-
tomatically infected people, χ t( )k a
A
, , from Ξ t( )k a,  and ηk,a(t) by dividing the total number of screening tests in a 
given year by the total number of people eligible to receive screening, accounting for the differential screening 
coverage between asymptomatically infected and uninfected people:
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parameter inference. We inferred the parameter values using Markov Chain Monte Carlo (MCMC) sam-
pling (Table 1)26. We ran five separate MCMC chains for 10,000 MCMC steps. We assumed a binomial likeli-
hood for the prevalence data and a negative binomial (NB) likelihood for the diagnoses data (Supplementary 
Information, part II). We checked convergence of the MCMC chains by computing the Gelman-Rubin conver-
gence diagnostic (<1.1)27.
Comparison of model variants. We used the chlamydia transmission model to investigate whether 
long-lasting partial immunity and differential screening coverage can explain discrepancies between 
model-predicted effects of screening and observed data in England. We considered four different model variants 
Figure 1. Schematic illustration of the C. trachomatis transmission model. S susceptible; IA asymptomatically 
infected; IS symptomatically infected; R partially immune; YA asymptomatic reinfection; YS symptomatic 
reinfection. Parameters are described in Table 1.
Parameter Description Unit Prior distribution Prior mean (95%CrI) Ref.
γ 1/duration of untreated asymptomatic infection (1/years) 1/years Normal (0.84, 0.02) 0.84 (0.80–0.88)
17
χS 1/duration of the symptomatic period 1/years Normal (11.1, 1.3) 11.1 (8.6–13.5) 33
ω Probability of successful infection clearance after treatment — Normal (0.74, 0.02) 0.74 (0.71–0.78)
43,44
β Per partnership transmission probability — Uniform (0, 1) 0.5 (0.025–0.975)
 Sexual mixing coefficient — Uniform (0, 1) 0.5 (0.025–0.975)
qM Fraction of symptomatic infections in men — Uniform (0, 1) 0.5 (0.025–0.975)
qF Fraction of symptomatic infections in women — Uniform (0, 1) 0.5 (0.025–0.975)
η1
Parameter 1 for per capita ratio of screening between 
infected and susceptibles — Uniform (1, 10) 0.5 (0.025–0.975)
log(η2)
Log transform of parameter 2 for per capita ratio of 
screening between infected and susceptibles — Uniform [−2, 1] −0.5 (−1.925–0.925)
κ Factor by which susceptibility to subsequent infection is reduced through partial immunity — Uniform (0, 1) 0.5 (0.025–0.975)
Table 1. Description of parameters used in the transmission model and their prior distributions.
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(Table 2). In models 1 and 2 we assumed no partial immunity (by fixing κ to zero), whereas models 3 and 4 can 
account for immunity (0 < κ ≤ 1, estimated using MCMC). In models 1 and 3, we assumed a differential screen-
ing coverage that does not change as screening increases in time, i.e. (η1 estimated using MCMC and fixing η2 to 
zero). In models 2 and 4 we allowed for a differential screening coverage that changes as screening increases (η1, e 
and η2 both estimated using MCMC). We compared the goodness of fit of the different model variants using the 
deviance information criterion (DIC)28,29. According to a rule of thumb, models with DIC within 1 or 2 points 
of the ‘best’ fitting model deserve consideration and models with DIC 3 or more points higher have considerably 
less support29.
Model code was implemented using R version 3.4.0 and can be obtained from https://github.com/joostsmid/
ct-screening.
Results
The posterior probability distributions for the model-estimated parameters were different for each model variant 
and resulted in a different goodness of fit (DIC) to the empirical data on C. trachomatis prevalence and diagnoses 
(Table 2). Comparing the DIC values allowed us to investigate the validity of the assumptions distinguishing the 
four model variants. A model including a decreasing per capita ratio of screening tests in infected compared to 
susceptible people and partial immunity (model 4) described the data better (lowest DIC) than models where 
the composition of the screened population was assumed fixed in time or without partial immunity (Table 2). 
A model including partial immunity but no changes over time in the composition of the screened population 
(model 3) fitted second best to the data with a 9 points’ higher DIC value when using the midpoints of the 
minimum and maximum estimates for tests and diagnoses. In a sensitivity analysis, using the minimum and 
maximum estimates, model 3 and 4 fitted equally well when using minimum estimates. When using maximum 
estimates, model 3 fitted best. In all scenarios, models without partial immunity fitted the data considerably worse 
(Supplementary Information, part III). Hence, our results with respect to partial immunity are robust to different 
assumptions about the data on tests and diagnoses. The evidence for a decrease in the proportion of tests done 
in chlamydia-infected individuals is less conclusive. Further results focus on the baseline scenario, with models 
fitted to the midpoint estimates.
Partial immunity decreased susceptibility to reinfection after natural clearance of a first infection by 68% 
(95% Bayesian credible interval (CrI) 46–87%) in model 4 (Table 2). The estimate of partial immunity in the 
second-best fitting model 3 (fixed per capita ratio of tests in infected compared to susceptible people) was similar 
(69%, 95% CrI 45–89%). When using minimum or maximum estimates for tests and diagnoses, estimates of par-
tial immunity were also similar (Supplementary Information, part III).
Figure 2 shows the posterior prevalence predicted by the best-fitting model 4 and the observed levels of C. 
trachomatis prevalence in England in 1999–2000 and 2010–2011. The uncertainty about the prevalence estimates 
from empirical data is large due to small sample sizes8,9. The model predicted a relative drop in prevalence for 
women between 15–24 years of 50% (95% CrI 44–54%) and for men between 15–24 years of 48% (95% CrI 
44–52%), also see Fig. 5. The mean model-predicted prevalence falls within the confidence intervals of the prev-
alence data for all age groups and both periods, with the exception of women aged 18–19 years in 2011. However, 
some inconsistencies remain between the observed and model-predicted chlamydia prevalence. In particular, for 
women the mean model-predicted prevalence is higher than the mean prevalence from data for 2000 and lower 
for 2011 for almost all age groups.
Empirical data show that the per capita number of diagnoses of C. trachomatis infections has increased 
between 2000 and 2011 (Fig. 3). Although model 4 could roughly reproduce this trend, some differences remain 
between the model fit and the data. In general, the model shows a less steep increase in the number of diagnoses 
from 2000 to 2011 for men and women between 20–24 years than was estimated by Chandra and colleagues7. 
Parameter
Model 1: posterior mean 
(95%CrI)
Model 2: posterior mean 
(95%CrI)
Model 3: posterior mean 
(95%CrI)
Model 4: posterior mean 
(95%CrI)
γ 0.85 (0.82, 0.89) 0.86 (0.82, 0.9) 0.84 (0.8, 0.88) 0.84 (0.81, 0.88)
χS 11.23 (8.79, 13.55) 11.23 (8.94, 13.76) 10.95 (8.52, 13.84) 11 (8.37, 13.6)
ω 0.73 (0.7, 0.77) 0.73 (0.7, 0.77) 0.74 (0.71, 0.77) 0.74 (0.71, 0.77)
β 0.6 (0.56, 0.65) 0.59 (0.56, 0.64) 0.82 (0.7, 0.92) 0.8 (0.71, 0.92)
 0.76 (0.5, 0.95) 0.8 (0.58, 0.97) 0.8 (0.58, 0.96) 0.84 (0.63, 0.97)
qM 0.14 (0.09, 0.2) 0.1 (0.04, 0.17) 0.15 (0.1, 0.2) 0.1 (0.04, 0.17)
qF 0.16 (0.07, 0.25) 0.11 (0.02, 0.21) 0.17 (0.09, 0.26) 0.11 (0.02, 0.23)
η1 1.99 (1.18, 2.84) 5.14 (2.08, 8.95) 2.29 (1.47, 3.26) 5.32 (2.24, 9.05)
η2 0* 1.06 (0.54, 1.62) 0* 0.93 (0.55, 1.30)
κ 0* 0* 0.69 (0.45, 0.89) 0.68 (0.46, 0.87)
Log likelihood −705.45 (−709.76, −702.33) −702.13 (−707.62, −698.42)
−692.63 (−697.86, 
−689.09) −689.96 (−695.26, −686.49)
DIC 1421 1420 1397 1388
Table 2. Summary of parameters (mean and 95% CrI of posterior distributions) for different models. In these 
models we used the midpoints of minimum and maximum estimates for tests and diagnoses from Chandra and 
colleagues7. For parameter inference. The last two rows show the fit statistics of the models. *Kept as fixed values 
in these models.
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For men aged 15–19 years, the model-predicted number of diagnoses increased more steeply than observed from 
data. Model fits for models 1–3 are shown in the Supplementary Information, part IV. Similarly, model 4 repro-
duced the trend in declining positivity rates of chlamydia tests over time (Fig. S12, Supplementary Information 
part V). There were some differences between model-predicted and observed positivity rates, particularly in men.
In model 4, differential screening coverage decreased in time (Fig. 4) due to increased testing and concur-
rent with increasing overall screening rates and screening rates in infected people (Figs S7–S9, Supplementary 
Information part V). The expected screening rate was in the full model 4.3 (95% CrI 2.2–6.6) times higher for 
infected than for uninfected women between 15–24 years in 2000; this decreased to 2.1 (95% CrI 1.4–2.9) in 2011. 
For men, this ratio decreased from 5.0 (95% CrI 2.2–8.2) in 2000 to 3.1 (95% CrI 1.9–4.4) in 2011 (Fig. 4). The 
Bayesian credible intervals around these estimates are large. For men and women aged 25–44 years, we found no 
decrease in the ratio. The decrease in differential screening coverage in the model is the consequence of increased 
testing volume and not of decreased chlamydia prevalence, but it can affect prevalence. To illustrate this, we 
considered the counterfactual scenario where differential screening coverage remained at the level from 2000, as 
estimated in model 4. We used the estimated posterior distribution for η1 and fixed η2 to zero. Simulating this sce-
nario resulted in considerably greater reductions in chlamydia prevalence than with model 4, in which differential 
screening coverage was allowed to change (Fig. 5).
Discussion
In this study, we compared four model variants in a compartmental model of C. trachomatis infection dynamics 
that includes partial immunity after natural clearance of infection and changes in differential screening coverage 
over time. In our baseline scenario with regard to the numbers of chlamydia tests and diagnoses, the model vari-
ant that fitted best to empirical data about C. trachomatis prevalence and diagnoses in England between 2000 and 
Figure 2. Fit of model 3 (full model) to age-specific chlamydia prevalence for men and women in 2000 and 2011. 
Grey boxes and horizontal lines: posterior mean and 95% Bayesian credible intervals. Black dots and vertical bars: 
Estimated prevalence from Natsal-2 (2000) and Natsal-3 (2011) (mean and 95% confidence intervals).
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2011 (model 4) included both partial immunity (a reduction of susceptibility of 46–87%) and a decreasing pro-
portion of screening tests done in infected people over time. Although both factors attenuate the model-predicted 
effectiveness of screening, the model including both factors still predicted a decrease of chlamydia prevalence 
between 2000 and 2011 of 45–55% in the age groups targeted for screening.
A strength of this study is the availability of time-series data about chlamydia testing and diagnosis data7, 
and repeated cross-sectional surveys of C. trachomatis prevalence and sexual behavioural data from the same 
population over the same time period22,23. The testing data avoided the need, in other modelling studies, for 
strong assumptions about (unobserved) levels of screening coverage11,13,30. Second, because of the importance of 
age as a risk factor for chlamydia, we included detailed age structure and age-dependent sexual behaviour in our 
model, which allowed us to estimate chlamydia prevalence in different age groups and fitted these to data about 
Figure 3. Fit of model 4 (full model) to age-specific per capita number of diagnoses for men and women 
between 2000 and 2011. Coloured lines and shaded areas: posterior mean and 95% Bayesian credible intervals. 
Vertical bars and dots: Minimum and maximum estimates for number of diagnoses from Chandra and 
colleagues7, and midpoints of these estimates (used for fitting).
Figure 4. Differential screening coverage: Model-estimated change in the ratio of the screening rates in infected 
vs. susceptible individuals for men and women of 16–24 years old between 2000 and 2011. Coloured lines and 
shaded areas: Posterior mean and 95% Bayesian credible intervals.
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age-specific prevalence and diagnoses24. We made optimal use of age-specific data to estimate the values about 
the unknown model parameters, including those quantifying immunity and the distribution of screening tests. 
Third, by synthesising the data in a Bayesian framework we could quantify the distinct effects of partial immunity 
and dynamic changes in the distribution of screening tests, whilst accounting for uncertainty about the model 
parameters.
Our study has also limitations. First, the testing and diagnosis data, rather than the chlamydia prevalence data 
mainly drove the Bayesian inference in our model. The statistical uncertainty of the prevalence data was higher 
than that of the diagnoses data, because the Natsal surveys included a small sample of the target population for 
two periods only (1999–2001 and 2010–2012), whereas the data about diagnoses are from the whole of England 
for each year between 2000–2011. Moreover, the prevalence data are probably reasonably accurate because they 
are from a well- characterised population, corrected for representativeness using post-stratification weights, but 
imprecise. The testing and diagnoses data are less accurate in the earlier years but very precise. To account for the 
lower accuracy of the diagnosis data, we modelled their likelihood using a negative binomial distribution instead 
of a Poisson distribution, which introduced a moderate dispersion in the diagnoses data. Second, the assumption 
of an exponential relationship between the total number of tests T in a given year and the per capita ratio of test-
ing in infected compared with susceptible people η(T) in that year might be an over-simplification of geograph-
ical and temporal changes in screening31. The phased geographical roll-out of the NCSP probably accounted for 
most of the increase in testing from 2003–2007. After nationwide implementation, when targets for screening 
coverage were introduced, an increasing proportion of tests was probably done in those at lower risk32. Then, an 
exponential function makes sense because convergence to one as the number of tests becomes large indicates the 
increasingly equal distribution of tests among all sexually active people. Third, we had to be selective about the 
parameters included in the model because the MCMC algorithm would otherwise not converge. We could, there-
fore, not consider all heterogeneity between individuals in susceptibility and biological response to infection. We 
assumed only one level of partial immunity, which is a likely over-simplification, given the possibility of heteroge-
neity in immune response at the level of the individual or strain-specific immunity, and potential effects of repeat 
infection. We also did not consider waning immunity. Further, we assumed that the transmission probabilities 
and duration of untreated asymptomatic infection were the same for men and women. There is much uncertainty 
about these estimates but our assumptions are in line with those used in other modelling studies33,34. It is unclear 
how these assumptions and levels of heterogeneity would affect our results. Finally, we assumed the sexual behav-
iour parameters to be fixed and did not consider changes in sexual behaviour between 2000–2011. Although 
there were only minor differences in sexual behaviour data between Natsal-2 and Natsal-322, we acknowledge 
that this is assumption may have caused discrepancies between the true and the model-predicted prevalence and 
incidence over time.
Mathematical modelling studies of C. trachomatis often over-estimate the effects of screening interventions 
on prevalence considerably when compared with empirical estimates in repeated cross-sectional studies. The 
results of our study suggest that including protective immunity after natural clearance of C. trachomatis10–14 and 
changes over time in the distribution of screening tests among modelled subpopulations helps to better account 
Figure 5. Model-estimated change in chlamydia prevalence in men and women between 2000 and 2011. 
Best-fit: Full model (model 4) including changes in the proportion of tests done in infected individuals and 
partial immunity (posterior mean and 95% Bayesian credible intervals). Hypothetical: Scenario in which the 
proportion of screening tests in infected individuals is kept at the same level as was estimated for 2000. Error 
bars for 2000: chlamydia prevalence in men/women aged 18–24 from Natsal-2; error bars for 2011: chlamydia 
prevalence in men/women aged 16–24 from Natsal-3 (mean and 95% confidence intervals).
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for the marginal change in chlamydia prevalence estimated in Natsal-2 and Natsal-3. However, our model did 
not fully reconcile the model predictions with the data either, with a model-predicted decrease of C. trachomatis 
prevalence between 2000–2011 that is still somewhat larger than expected from data9. According to our model, 
screening and treating C. trachomatis-infected people resulted in a reduction in prevalence even when account-
ing for immunity. This finding does not support the results of a modelling study that suggested that widespread 
testing and treatment diminish population level immunity and can result in an increase in incidence and preva-
lence35. Other factors have been proposed as reasons for the similarity of estimated C. trachomatis prevalence in 
the Natsal-2 and Natsal-3 surveys. First, increases in sexual risk-taking behaviour could have resulted in increased 
transmission of C. trachomatis, countering the effects of screening. However, amongst the sexual behaviours 
measured in Natsal-2 and Natsal-3, the only difference among heterosexual adults was a slight decrease in the 
proportion of men with multiple partners with whom no condoms was used22. We do not believe that this change 
would be sufficient to abolish the model-predicted reduction in prevalence and we did not investigate this possi-
bility because our model did not explicitly include condom use. Second, a temporary reduction in C. trachomatis 
prevalence could have occurred during the period between the Natsal surveys. In the modelling study by Lewis 
and White, which also used the data on chlamydia testing and diagnoses reported by Chandra and colleagues, 
model-inferred prevalence decreased until 2008 and then increased back to baseline, attributed to a decrease 
in testing by the authors15. That model did not take into account differential screening coverage over time and 
inferred large increases in incidence to balance the increase in screening rates36. In theory, a reduction in the rate 
of successful partner notification could also limit the impact of a chlamydia screening intervention. However, in 
a study that compared a pair model including partner notification with a simpler model without partnerships37, 
changes in partner notification rates resulted in very modest changes in incidence. Third, it has been suggested 
that C. trachomatis transmission is maintained by infection in the female rectum that is not adequately treated38,39. 
We deemed an analysis of the role of anorectal infections beyond the scope of this study because of the uncer-
tainty about autoinoculation probabilities.
Our findings have implications for future research and for public health. Mathematical modelling often pro-
vides the first indications about the potential effects of interventions to control infectious diseases. Arguably, data 
from population-based studies, preferably from randomised controlled trials, should be obtained to inform fur-
ther modelling of future impact before the introduction of a screening programme. For C. trachomatis, chlamydia 
testing became widespread before either modelling or trials had been conducted. Public health decision-makers 
and researchers should jointly determine requirements for monitoring and epidemiological, clinical and basic 
research that will address gaps in the evidence. Clinical immunological studies that can provide more information 
about the strength and duration of immunity following natural clearance of C. trachomatis would be very valua-
ble. Definitive answers will have to await the outcomes of ongoing research for better validated serological mark-
ers of immunity than we have at present40. Our model predicted a larger reduction in C. trachomatis prevalence 
if the ratio of screening coverage in infected compared with uninfected individuals remained high. This finding 
has implications for defining targets for screening performance. After 2011 in the NCSP in England, targets for 
screening coverage were replaced by indicators for diagnosis rates to maintain high levels of diagnosed infections 
for a given test volume41. This resulted in a decreased testing volume but an increased percentage testing positive. 
The optimal diagnosis rate and its relationship with population prevalence, however, remains unknown42, so 
further data about the relationship between sexual behaviour, chlamydia testing and its outcomes in different 
subpopulations over time are needed.
In conclusion, the results from our baseline scenario suggest that partial immunity against reinfection and 
changes in differential screening coverage over time might have limited the reduction in C. trachomatis preva-
lence that would be expected for the level of screening coverage achieved in England. The full range of factors that 
account for discrepancies between the observed data and model-predictions of changes in C. trachomatis preva-
lence has not been elucidated. To reduce the gap between modelling and data, advances are needed in knowledge 
about factors influencing the coverage of chlamydia screening, the immunology of C. trachomatis and changes in 
C. trachomatis prevalence at the population level.
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